xRead - September 2022

Wise et al.

Page 367

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study design Study groups Clinical endpoint Conclusion 3 Placebo

Golden et al. 1225 2000 1b DBRCT 1 Azelastine 0.56 mg BID; 2 Placebo RSS, ESS Azelastine superior to placebo for improving rhinorrhea and sleep quality. Berger et al. 1226 1999 1b DBRCT 1 Azelastine 0.56 mg BID; 5-item symptom score, global evaluation

Azelastine at least as effective as combination therapy with loratadine plus beclomethasone spray.

2 Loratadine 10-mg tablet daily + beclomethasone dipropionate 0.168 mg spray BID 2 Budesonide 0.256 mg spray daily; 3 Placebo 3-item symptom score Budesonide superior to azelastine; both treatments superior to placebo. Herman et al. 1228 1997 1b DBRCT 1 Azelastine 0.28 mg BID; 2 Placebo Stern et al. 1227 1998 1b DBRCT 1 Azelastine 0.28 mg BID;

TNSS Azelastine superior to placebo for children.

6-item symptom score Beclomethasone superior to azelastine for long-term symptom improvement; both

treatments superior to placebo; azelastine more rapid onset.

over placebo in patients already treated with systemic azelastine.

3 Chlorpheniramine 12-mg tablet BID; 4 Placebo 8-item symptom score Azelastine superior to placebo at both doses; no comparison with chlorpheniramine. Charpin et al. 1232 1995 1b DBRCT 1 Azelastine 0.28 mg BID;

2 Cetirizine 10-mg tablet daily 8-item symptom score Azelastine superior for nasal stuffiness and rhinorrhea; no difference in other symptoms. Pelucchi et al. 1233 1995 1b DBRCT 1 Azelastine 0.28 mg BID;

Azelastine superior to placebo and comparable to beclomethasone for symptom improvement; neither treatment prevented bronchial responsiveness; no effect of azelastine on eosinophils.

13-item symptom score Azelastine spray showed limited benefit 8-item symptom score, nasal lavage, methacholine challenge

Newson-Smith et al. 1229 1997 1b DBRCT 1 Azelastine 0.56 mg BID;

2 Beclomethasone 0.2 mg spray BID; 3 Placebo

Weiler & Meltzer 1230 1997 1b DBRCT 1 Azelastine 0.56 mg spray BID + azelastine 0.5 mg tablet BID; LaForce et al. 1231 1996 1b DBRCT 1 Azelastine 0.56 mg daily; 2 Azelastine 0.56 mg BID;

2 Placebo spray + azelastine 0.5-mg tablet BID

2 Beclomethasone dipropionate 0.1 mg spray BID;

Study Year LOE

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.